



DEPARTMENT OF THE ARMY
HEADQUARTERS, US ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND
810 SCHREIDER STREET
FORT DETRICK, MARYLAND 21702-5000

July 14, 2020

Dr. Remington Nevin
MuckRock News
DEPT MR 83647
411A Highland Avenue
Somerville, MA 02144-2516

Dear Dr. Nevin:

This letter is in response to your Freedom of Information Act (FOIA) request that was sent to Ms. Shalli Keller, Staff Action Control Officer, U.S. Army Medical Research and Development Command (USAMRDC). You indicated in this request that you were seeking the following: "All records, including purchase records, billing, and shipping information, and associated correspondence, related to the 2019 purchase by the U.S. Army of a supply of tafenoquine (Arakoda™). As noted in a recent press release (Caution-<https://www.prnewswire.com/news-releases/arakoda-tafenoquine-tablets-first-prescription-drug-approved-for-malaria-prevention-by-us-fda-in-over-18-years-now-available-in-us-300962690.html>), the "first significant shipment of Arakoda occurred in September, 2019 to the U.S. Army".

Your request has been forward to the U.S. Army Medical Research Acquisition Activity (USAMRAA) for direct response and assigned Case Number: FP-20-008014. In an email dated December 9, 2019, Ms. Gaynor of my staff outlined her understanding of the scope of your request. You indicated in your response the following: "The materials you describe related to the purchase, billing, and shipping, I would consider responsive to my request. In addition to these, as per my request, please also search for any associated correspondence, such as emails, related to these, as it would appear probable that there would be a significant volume of correspondence created in arranging for the contracted purchase of this drug".

Our office indicated in the initial response dated February 12, 2020, that you would receive additional responsive records as they became available. Attached please find additional records. Our office is currently working on processing the remaining records responsive to your request. Responsive records will be provided to you as they become available on a rolling basis.

Redacted information has been done so pursuant to the following FOIA exemptions:

- 5 U.S.C. § 552(b)(4): Records have been redacted to protect trade secrets and commercial or financial information obtained from a person that is privileged or confidential. In addition, the information being protected is done so as it is current and if released could compromise the submitter's profit margin on the contract price, labor rates, or staffing and subcontractors.

- 5 U.S.C. § 552(b)(6): Records have been redacted where the disclosure of information would represent a clearly unwarranted invasion of personal privacy. The type of information withheld under Exemption 6 includes names, signatures, email addresses and/or telephone numbers. We have determined that the privacy interest of this information outweighs any public interest in its release.

Because your request has been partially denied, you are advised of your right to appeal this determination to the Secretary of the Army. If you decide to appeal at this time, your appeal must be submitted within 90 days of the date of this notification. In your appeal, you must state the basis for your disagreement with the partial denial and the justification for the release of information associated with your request for this command. Your appeal should be addressed to: U.S. Army Medical Research and Development Command, Attention: FCMR-AAZ-A, 820 Chandler Street, Fort Detrick, Maryland 21702-5014, for forwarding, as appropriate, to the Office of the Secretary of the Army. Please enclose a copy of this response along with your Appeal. To ensure proper processing, the letter and the envelope should both bear the notation, "Freedom of Information Act Appeal."

You are also advised of your right to seek dispute resolution services pertaining to your concerns from the USAMRAA FOIA Public Liaison Officer, Ms. Erin K. Cross at (301) 619-2540 or email: erin.k.cross.civ@mail.mil.

If you have further questions regarding this request, please direct them to Ms. Nancy Gaynor at 301-619-2389 or email at nancy.a.gaynor.civ@mail.mil.

Sincerely,

Christopher E. Sherman
Initial Denial Authority

Enclosures